a b s t r a c t 2-ethylhexyl-2,3,4,5 tetrabromobenzoate (TBB) is used as a flame retardant. Biomonitoring for TBB exposures include the metabolite, tetrabromobenzoic acid (TBBA), in urine. We derived a Reference Dose (RfD) for TBB and a Biomonitoring Equivalent (BE) for TBBA in urine. Three longer-term studies of oral gavage dosing of a commercial mixture BZ-54 (which includes 70% TBB) in rats were evaluated for deriving the RfD. The 95% lower confidence limits on the BMD associated with a 1 SD change from the mean (BDML SD ) values ranged from 77 to 134 mg/kg-day. The mean BMDL SD value of 91 mg/kg-day for maternal body weight changes was selected as the appropriate point of departure (POD), corresponding to a human equivalent dose (POD HEC ) of 25 mg/kg-day. A total composite uncertainty factor (UF) of 300 yields an RfD of 0.08 mg/kg-day. A urinary mass excretion fraction (Fue) of 0.6 for TBBA following oral doses of TBB in rats was used to calculate BEs for TBBA in urine of 2.5 mg/L and 2.5 mg/g cr. Mean (5.3 Â 10 À6 mg/L) and maximum (340 Â 10 À6 mg/L) levels of TBBA measured in urine from human volunteers reported in the literature indicates margins of safety (MOS) are approximately 450,000 and 7,000, respectively.
Introduction
The chemical 3, 4, 5 tetrabromobenzoate (CAS # 183, mw ¼ 549.92, C 15 H 18 Br 4 O 2 ) is used as a brominated flame retardant. Brominated flame retardants have received increased scrutiny, since the late 1990s, when polybrominated diphenyl ethers were found in samples of human blood (Sj€ odin et al., 1999) and milk (Meironyt e et al., 1999) . Because biomonitoring brought about early detection of brominated flame retardants in these sample types, biomonitoring samples of today for brominated flame retardants is often included during exposure assessments. As a result, there is a need for methods to interpret the biomonitoring levels reported for brominated flame retardants in a public health risk context. This paper provides such an approach for interpreting biomonitoring data for 2-ethylhexyl-2,3,4,5 tetrabromobenzoate (TBB) and its metabolite tetrabromobenzoic acid (TBBA; CAS # 27,581-13-1, mw ¼ 437.7, C 7 H 2 Br 4 O 2 ).
Since there is a lack of guidance values for interpreting biomonitoring data for most environmental chemicals, these data are typically presented without any interpretation in the context of potential health risks. Interpretation of biomonitoring data in the context of potential health risks would ideally be done using guidance values based on robust datasets that relate potential adverse effects to biomarker concentrations in human populations (see, for example, the US Centers for Disease Control and Prevention (CDC) blood lead level of concern; http://www.cdc.gov/nceh/ lead/). However, development of such epidemiologically-based guidance values is a resource-and time-intensive effort, and in practice, data to support such assessments exist for only a few chemicals. As an interim approach, the concept of Biomonitoring Equivalents (BEs) has been developed (Hays et al., 2007) , and guidelines for the derivation and communication of these values have been prepared.
A BE is defined as the concentration or range of concentrations of a chemical or its metabolites in a biological medium (blood, urine, or other medium, including tissue biopsies) that is consistent with an existing health-based exposure guidance value such as a reference dose (RfD) or Tolerable Daily Intake (TDI). Existing chemical-specific pharmacokinetic data are used to estimate biomarker concentrations that are consistent with the Point of Departure (POD) used in the derivation of an exposure guidance value (such as the RfD or TDI), and with the exposure guidance value itself. BEs can also be derived for other types of exposure guidance factors, including recommended intakes of nutritionally essential elements . BEs can be estimated using available human or animal pharmacokinetic data , and BEs have been derived for over 100 compounds (most recently reviewed in Aylward and Hays, 2011; www. biomonitoringequivalents.net) .
BEs are intended to be used in the same way that the underlying exposure guidance values are used and upon which they are based. Thus, BEs carry the same functional definition as the underlying guidance value for which they are derived. BE values for multiple chemicals have been used to evaluate nationally representative biomonitoring data in Canada and the United States across chemicals to examine relative levels of exposure in the context of risk assessment-derived exposure guidance values (St-Amand et al., 2014; Aylward et al., 2013) .
The BEs derived here for TBB and TBBA will allow for the interpretation of important biomonitoring data currently available and those that become available in the future.
Methods
Derivation of a BE requires the selection of the most appropriate biomarker(s) available for the compound, exposure guidance values (or points of departure) of interest, and pharmacokinetic data/model(s) required to convert the exposure guidance value(s) into the chosen biomarkers (Hays et al., 2007) . The following, outlines how each of these factors are determined to offer the best fit for use.
Biomonitoring data
TBB is rapidly metabolized to TBBA in vitro by the liver and intestinal subcellular fractions in both rat and humans via cleavage of the 2-ethylhexyl chain without requiring any added cofactors (Roberts et al., 2012) . In the rodent, TBBA is rapidly excreted via urine following oral dosing of TBB Knudsen et al., 2014) . Biomonitoring studies are available that have measured both TBBA in human urine samples Butt et al., 2014) and TBB in human blood and milk samples (Zhou et al., 2014) (Table 1) . TBBA in urine appears to be specific to TBB exposures because TBBA is not produced by any other known parent compounds and TBBA is not known to exist as an environmental degradant of TBB. As a result, TBBA is identified as a specific biomarker for TBB exposures. TBB in blood is likewise specific to exposures to TBB, since TBB is not known to be a metabolite of any currently known compound. TBBA in urine has the advantage of being collected with relatively non-invasive techniques, while TBB in blood is more invasive since blood must be collected via venipuncture. However, both TBBA in urine and TBB in blood are reasonable biomarkers for assessing exposures to TBB. Since the mode of action for the toxicity of TBB is not clearly known, it is likewise unknown whether TBB and/or TBBA is actually a proximate toxicant. Therefore, at this time, neither biomarker has an advantage with respect to these noted factors.
Risk assessment
No regulatory agencies have developed a risk assessment for TBB to date. Unpublished toxicology studies for TBB (via dosing of BZ-54; 70% TBB and 30% TBPH) were provided to the authors for the purpose of conducting an independent risk assessment (WIL, 1997; MPI, 2008a,b) . The process and outcome of the risk assessment follows:
An oral reference dose (RfD) was derived for TBB using the following equation:
RfD ¼ POD HED =UF T Where, RfD ¼ Reference dose (mg/kg-day); POD HED ¼ Human equivalent dose for the point of departure; and UF T ¼ Total uncertainty factor, calculated as the product of individual uncertainty factors for interspecies variation (UFa), intraspecies variation (UFh), LOAEL-to-NOAEL (UFl), subchronicto-chronic extrapolation (UFs), and database deficiencies (UFd).
A dose-response assessment analysis was conducted for TBB using methods consistent with USEPA guidelines (USEPA, 2002; , and consists of a number of steps, including: (1) selection of data sets; (2) selection of a dose measurement; (3) doseresponse modeling; (4) selection of a point of departure; and (5) selection of uncertainty factors. Each of these individual five steps is summarized below:
Data sets
Toxicity studies available for TBB include three unpublished reports: (1) a 28-day toxicity study in rats (WIL, 1997); (2) a developmental toxicity study in rats (MPI, 2008a) ; and (3) a twogeneration reproductive toxicity study in rats (MPI, 2008b) all of which were exposed to BZ-54, which is 70% TBB and 30% TBPH.
2.2.1.1. 28-Day toxicity study (WIL, 1997) . Groups of 6 rats per sex were administered oral (gavage) doses of 0, 160, 400, or 1,000 mg/ kg-day BZ-54-via corn oil for 28 days (WIL, 1997) . The authors noted clinical findings of a relaxed vaginal opening in all treated female groups, and salivation in both sexes in the highest dose group. Food consumption and body weights were reduced in the highest dose group males, and in the low, mid and high dose group females. Renal tubule epithelial regeneration was reported in all male treatment groups in a dose response manner, including 100% of exposed female animals. The study authors concluded that this study identified a LOEL of 160 mg/kg-day.
2.2.1.2. Developmental toxicity study (MPI, 2008a) . Groups of 25 female rats were administered oral (gavage) doses of 0, 50, 100, or 300 mg/kg-day BZ-54 via peanut oil on gestation days 6 through 19 (MPI, 2008a) . The authors noted maternal toxicity (lower gestational food consumption and body weight gains, sparse abdominal hair) in animals from the mid and high dose groups. Fetal body weights were also reduced in these two dose groups. In the highest dose group, skeletal malformations (fused cervical neural arches) and variations were noted in a small number of fetuses. The study authors concluded that this study identified a NOAEL of 50 mg/kgday.
2.2.1.3. Two-generation reproductive toxicity study (MPI, 2008b) . Groups of 19e23 female rats were administered oral (gavage) doses of 15, 50, or 165 mg/kg-day BZ-54 via peanut oil for at least 10 weeks prior to mating that continued through mating, gestation and up to lactation day 21 (MPI, 2008b) . The authors noted lower body weights and body weight gains in parental and F1 females, and to a lesser extent in F1 males. Lower body weights and spleen weights were found in pups for both generations. No other treatment-related effects were found. The study authors concluded that this study identified a parental and neonatal toxicity NOAEL of 50 mg/kg-day, while the NOAEL for reproductive performance and fertility effects was 165 mg/kg-day. All three toxicity studies were conducted in the same strain of rats (CD[Crl:CD(SD)]). Of these studies, the two-generation reproductive toxicity study was selected as the best choice for deriving a reference dose since it: (1) included a longer exposure duration than the other two studies; (2) assessed a lower range of doses than the other two studies; and (3) included a higher number of animals per treatment group (>40 when P0 and F1 animals are considered together). Continuous data sets from this study identified for benchmark dose (BMD) analyses include changes in parental body weights (P0 and P1 female rats), changes in pup body weights (F1 and F2 male and female pups), and changes in pup spleen weights (F1 and F2 male and female pups) (Tables 2 and 3 ).
Dose measure
All doses were assessed in terms of administered dose (mg/kgday). All adjustments to dose (e.g., for discontinuous exposure, human equivalent dose calculation) were performed on the point of departure (POD). All administered doses of BZ-54, and thus toxicity, were assumed attributed to TBB. No corrections for percent content of TBB were made.
Dose-response modeling
All dose-response modeling was performed using USEPA's Benchmark Dose Software (BMDS, version 2.6). Continuous models were used to fit dose-response data for body and spleen weight changes. For each data set, the best fitting model was selected based on Akaike information criterion (AIC; lower value indicates a better fit), chi-square goodness of fit p-value (higher value indicates a better fit), ratio of the BMC:BMCL (lower value indicates less model uncertainty), and visual inspection of model behavior.
Point of departure
Consistent with USEPA guidelines for modeling continuous data sets (USEPA, 2012), the dose corresponding to an increase in the mean response equivalent to one standard deviation in unexposed animals (BMDSD) and its 95% lower confidence limit (BMDLSD) were selected as appropriate points of departure.
POD values were converted to human equivalent dose (HED) values by using allometric scaling of dose using body weight raised to the ¾ power (USEPA, 2011): For these body weights and scaling factor, an HED is equal to (0.42/70) 0.25 or 0.28 times the animal dose (AD).
Uncertainty factors
Individual uncertainty factors (UFa, UFh, UFl, UFs, UFd) were defined based upon available information for TBB and current practices. For deriving RfD values, a total uncertainty factor consisting of the sum of each individually assigned level of uncertainty within the range of 1e10 was used for factors of interspecies variation, intraspecies variation, and deficiencies in the database. Because of potential overlap in these uncertainty factors, the total uncertainty factor value is typically capped at a value of 3000 in deriving reference values (USEPA, 2002).
Pharmacokinetic data
The second factor required for derivation of the BE relates to the pharmacokinetic (PK) conversion of an external dose of TBB (e.g., mg/kg-day) into a corresponding concentration of TBB in blood or TBBA in urine (e.g., mg/L).
The PK data required for deriving a BE for TBB in blood is either PK data, model or relationships in either the species used in the toxicity tests used to derive the RfD (in this case the rat), or in humans. At this time, there are not sufficient data available to derive a BE for TBB in blood.
The PK data required for calculating a BE for TBBA in urine is the urinary mass excretion fraction (Fue) of TBBA excreted in urine following an oral dose of TBB. Hoffman et al. (2014) quantified the amount of TBBA excreted in urine following a single oral (gavage) dose of 1 mg Firemaster 550 (which equates to 0.35 mg of TBB e personal communication with Chemtura). Hoffman et al. measured the concentration of TBBA in urine of rats up to 24 h post-dosing, but they did this by transferring each rat to a new cage to stimulate urination at 1, 3, 6 and 24 h post-dosing (i.e., they did not collect all urine voids throughout the 24 h post-dosing period). As a result, the data collected using this study design significantly under-estimated the actual Fue. Knudsen et al. (2014) dosed mice and rats to single and multiple doses of radio-labeled TBB. Total radioactivity was measured in urine and feces for up to 72 h post dosing. In urine, three metabolites were identified; TBBA, and sulfate and glycine conjugates of TBBA. No parent TBB was identified in urine. The percent of radio-activity excreted in urine decreased with increasing dose; 54% at a single oral dose of 0.1 uMol/kg, 47% at 1 uMol/kg, 37% at 10 uMol/kg and 44% at 100 uMol/kg. The percent of total radioactivity excreted in urine increased with longer durations of dosing; 54% following a single oral dose of 0.1 mmol/kg, 67% following 5 doses, and 66% following 10 oral doses of 0.1 mmol/kg. The Knudsen et al.
(2014) results indicate that urinary excretion fractions at lower doses (and perhaps for extended periods of exposure) are most likely to be relevant for actual human exposures in the environment. Thus, the Fue of 0.6 (rounded down to 1 significant figure) was used to derive the BEs. Knudsen et al. (2014) also quantified total radioactivity in blood following oral and iv dosing. Total radioactivity in blood peaked around 4 h post-dosing. The half-life of elimination was 5 h. Because only total radioactivity was measured and the authors did not report the identity of compounds present in blood (e.g., TBB or TBBA), the blood data cannot be used to derive a BE for TBB in blood.
Results

Dose-response assessment
A total of 9 continuous data sets (2 for body weight changes in dams; 4 for body weight changes in pups; 3 for spleen weight changes in pups) were assessed using BMD methods. Statistically acceptable fits (goodness-of-fit p-value>0.10) were obtained for 8 data sets, and the fit for the remaining data set approach statistical acceptance (p ¼ 0.091), and was therefore retained. BMD results for these data sets were remarkably similar, with BMD SD values ranging from 104 to 228 mg/kg-day, and BMDL SD values ranging from 77 to 134 mg/kg-day (Table 4 ). The mean BMD SD value for maternal body weight changes (126 mg/kg-day) was slightly lower than those obtained for the other two endpoints (166 and 152 mg/ kg-day, respectively), which was consistent with maternal toxicity that was the likely causation of producing effects in pups. For this reason, the mean BMDL SD value of 91 mg/kg-day for maternal body weight changes was selected as an appropriate point of departure. This value corresponds to a human equivalent dose (POD HED ) of 25 mg/kg-day.
Individual uncertainty factors selected for the oral RfD are summarized below:
Interspecies (UFa) -Because allometric scaling was used to calculate human equivalent doses for the point of departure, and thereby reducing uncertainty associated with interspecies extrapolation, a reduced uncertainty factor of 3 is sufficient to account for interspecies variation in toxicodynamic factors (USEPA, 2011) . Intraspecies (UFh) e A default value of 10 was retained for intraspecies variation in humans.
Subchronic-to-chronic (UFs) e Although the exposure duration in the critical study is not equivalent to a lifetime exposure, it does include exposures for more than 10 weeks prior to mating, mating, gestation and through to lactation day 21, which exceeds 10% of a rats expected lifetime. Therefore, a value of 1 is considered appropriate for UFs. LOAEL-to-NOAEL (UFl) e Because BMD methods were used in this assessment, a value of 1 is considered appropriate for UFl (i.e., there is no need for adjustment when using a LOAEL value). Database deficiency (UFd) e The toxicity database for TBB is limited to three studies of longer duration using a multiple dosing regimen and all conducted within a single species, the rat. In addition, some uncertainty is associated with the presence of kidney effects observed in the 28-day toxicity study (WIL, 1997) . This finding was not observed in the key study despite the use of the same species, having a longer exposure duration, and within an overlapping range of doses. For this reason, a value of 10 is considered appropriate for UFd.
Based on these individual uncertainty factor values, a total uncertainty factor of 300 (3 Â 10 Â 1 Â 1 Â 10) is considered appropriate for calculating an RfD for TBB. Application of a total uncertainty factor of 300 to the POD HED value of 25 mg/kg-day results in an RfD value of 0.08 mg/kg-day (expressed to 1 significant figure) for TBB.
Biomonitoring Equivalents
A BE is derived for TBBA in urine using the urinary mass balance approach;
Where, RfD e Reference Dose (mg/kg-day) F UE e urinary excretion fraction (unitless). 0.6 (Knudsen et al., 2014) V 24 e Age dependent 24-h urinary flow rate (ml/kg-day); 30, 25, 20, 20 mL/kg-d for age ranges 3 to <6, 6 to <10, 10 to <18 and >18 years of age, respectively (Aylward et al., 2015) . CR 24 e Age-dependent 24-h creatinine excretion rate (mg/kgday); 16, 19, 21 and 20 mg cr/kg-d for age ranges 3 to <6, 6 to <10, 10 to <18 and >18 years of age, respectively (Aylward et al., 2015) .
Age range-specific BEs were calculated (Table 5) . BE PODs ranged from 170 to 250 mg/L and BEs ranged from 1.7 to 2.5 mg/L, with the lower end of the range being for the youngest age group (3 to <6 years of age). BEs for analytes in urine, in which Fue is not a function of age, are lowest in the youngest age groups since daily urine flow rate tends to decrease with increasing age. 
Margin of safety
A margin of safety (MOS) can be calculated using;
MOS ¼ BE=HBM 
Discussion
Assessing exposures to chemicals in the environment and in consumer products can be difficult, especially when exposures may occur via multiple sources and routes and may not be consistent.
The flame retardants have the added complexity of exposure sources; for example, dust emissions from consumer products in the home and workplace (Hays et al., 2006) . As a result of this difficulty, more researchers and government agencies are relying more on biomonitoring in order to assess exposures amongst humans, either as part of epidemiology studies or as regional and/ or national exposure and health monitoring programs. The BEs created here can be used to interpret existing and future biomonitoring data for TBB in a public health risk context. The first step in the derivation of the BEs presented here was to derive risk values for TBB. Robust guideline designed toxicology studies for BZ-54 were made available for review. All endpoints were considered and BMD software was used to fit dose-response curves to the data from the various studies and endpoints measured. The derived risk value (Reference Dose) derived within is 0.08 mg/kg-day and should be considered of medium confidence. This is due to the limited number of toxicology studies conducted in a single species of animal (hence the need for the UFd of 10 to account for database deficiencies). The RfD was derived to be consistent with US EPA and other agency derivations.
Studies that included dosing with BZ-54 were considered most appropriate for a risk assessment for TBB. An oral dosing study using Firemaster 550 was also available, but was considered less applicable since it contains a lower percent of TBB (less than 25%) and contains phosphorous reaction product mixtures of triphenyl phosphate(TPP) and a mixture of isopropylated triphenylphosphate isomers (IPTPP). The phosphorus reaction product mixture (TPP & IPTPP) has its own hazards (https://echa.europa.eu/registrationdossier/-/registered-dossier/13333/7/6/2), thus the toxicology study with Firemaster 500 was deemed less relevant for derivation of an RfD for TBB.
BEs were derived for analytes excreted in urine using a mass balance approach. This approach requires determining the mass or molar fraction of an exposed dose that is excreted in urine, preferably in humans. To date, all BEs for analytes in urine have relied on human controlled dosing studies to determine this molar/mass fraction. For TBB/TBBA, no such human data exists. However, data does exist in rats and mice exposed orally to TBB. The Fue for any compound is dependent on how the compound is metabolized and the metabolites (or parent compound) is eliminated from the body. For TBB, the metabolism has been shown to be qualitatively identical between human and rat; with TBBA being the primary metabolite (via cleavage of the ethylhexyl chain) and the rate of metabolism is fast in hepatic cells from both species (Roberts et al., 2012) .
The Fue estimate derived from the rat (Knudsen et al., 2014) included free TBBA and TBBA conjugates. This potentially helps to (Aylward and Hays, 2011) . The Fue of 0.6 used from Knudsen et al., 2014was obtained from a single oral dose. Knudsen et al. also administered 5 and 10 daily doses of TBB and determined the percent of total radioactivity eliminated in urine and feces, but they did not quantify only TBBA and conjugates in this part of the study. The authors found statistically significant increases in total radioactivity eliminated in urine and a decrease in total radioactivity eliminated in feces with the 5 and 10 daily doses compared to the single oral dosed animals. This would suggest some form of induction of either metabolism or renal excretion with repeated dosing. However, since the authors did not quantify TBBA and conjugates with repeated dosing, a Fue for repeated dosing could not be used. Using a higher Fue would yield higher BEs and thus be less conservative. Therefore, use of the Fue from a single oral dose of 0.6 would be conservative with regard to this issue.
The available biomonitoring data for TBB is limited (Zhou et al., 2014; Hoffman et al., 2014; Butt et al., 2014) and thus the MOS estimates reflect this limitation. However, detection limits were sufficiently low, and therefore, yielded quantifiable levels of TBBA in urine. Hoffman et al. (2014) collected repeat samples from human volunteers over a 5-day period. The data indicate urinary TBBA is highly variable within an individual, yielding a relatively low intra-class correlation coefficient (ICC) of 0.56. A low ICC is consistent with a compound in which exposures are infrequent and/or the half-life of elimination is rapid. This would then suggest that upper percentiles on HBM biomonitoring samplings from a population are not likely to be very indicative of an average for longer-term exposures (Aylward et al., 2012 (Aylward et al., , 2014a . Therefore, the MOS at the maximum HBM concentration is most likely to be conservative if the maximum concentration reported in Hoffman et al. (2014) is indicative of the maximum urinary concentrations of TBBA amongst the broader population. If future national large scale biomonitoring programs (e.g., NHANES, CHMS) include TBB and/or TBBA, this will provide more confidence in the populations' exposures to TBB compounds and to more robust estimates of the MOS amongst the larger population.
The MOS of~450,000 calculated here for TBB via the mean measures of TBBA in urine for adults and approximately 230,000 for children puts TBB amongst the chemicals with the largest MOS of those interpreted using the BEs (Aylward et al., 2013) . In fact, the largest MOS measured to date using the BEs has been~1000. This would suggest the MOS of TBB in the environment at the current time is extraordinarily large. This suggests current uses of TBB have little potential for adverse impacts to public health and thus low priority for risk management.
The RfD derived is considered to be of medium confidence as a result of the toxicology studies being conducted in only one species. As more toxicology studies become available for TBB, the RfD can be revisited. Likewise, the BE estimates derived here can be updated once a human based Fue becomes available. In the meantime, the MOS estimates derived here can help make formative decisions about prioritization for TBB.
